Agency instructs imaging centers on possible closures and surveys.
Amid calls for all non-emergent imaging to be postponed during the COVID-19 outbreak, the U.S. Food & Drug Administration (FDA) announced additional guidance for breast imaging late last week.
“Protecting the health and safety of our staff and their families is of paramount concern to the U.S. Food & Drug Administration,” Commissioner Stephen Hahn, M.D., said in a statement. “As a nation, we must do everything we can to help slow the spread of the virus and help flatten the curve of the COVID-19 pandemic.”
On March 18, the FDA announced inspections for breast imaging facilities, including those contracted at the state level, would be suspended. In guidance, published March 19, the agency went further, detailing next steps for any imaging practices that choose to shut down during the crisis. The agency’s Division of Mammography Quality Standards announced it will offer “regulatory flexibility” for breast imaging providers facing various circumstances.
In its guidance, the FDA outlined three possible scenarios and how radiologists should respond:
The FDA said it will continue to monitor the situation as it unfolds and pointed anyone with questions to call 800-838-7715 or email MQSAhotline@versatechinc.com.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.